Molecular structure of Narciclasine, CAS Number: 29477-83-6
Narciclasine (CAS 29477-83-6)
See product citations (3)
Alternate Names:
(2S,3R,4S,4aR)-3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one
Application:
Narciclasine is an antiproliferative and pro-apoptotic inducer
CAS Number:
29477-83-6
Purity:
≥99%
Molecular Weight:
307.26
Molecular Formula:
C14H13NO7
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Exhibits antiproliferative and pro-apoptotic effects in carcinoma cells and displays cytotoxic activity against a panel of 60 cancer cell lines (mean IC50 = 47 nM). Activity decreases rate of cell division and increases mitosis duration in vitro. Also modulates the Rho/ROCK/LIM kinase/cofilin pathway stimulates RhoA activation and induces actin polymerization.
Narciclasine (CAS 29477-83-6) References
- Narciclasine as well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against brain cancers. | Van Goietsenoven, G., et al. 2013. Med Res Rev. 33: 439-55. PMID: 22419031
- Narciclasine - an Amaryllidaceae Alkaloid with Potent Antitumor and Anti-Inflammatory Properties. | Fürst, R. 2016. Planta Med. 82: 1389-1394. PMID: 27542176
- Narciclasine exerts anti-inflammatory actions by blocking leukocyte-endothelial cell interactions and down-regulation of the endothelial TNF receptor 1. | Stark, A., et al. 2019. FASEB J. 33: 8771-8781. PMID: 31017817
- Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2. | Bräutigam, J., et al. 2019. J Mol Cell Cardiol. 135: 97-108. PMID: 31381906
- Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses. | Kingsley, MK., et al. 2020. Sci Rep. 10: 2947. PMID: 32076015
- Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma. | Gopalakrishnan, R., et al. 2020. Sci Rep. 10: 5712. PMID: 32235878
- Narciclasine attenuates LPS-induced acute lung injury in neonatal rats through suppressing inflammation and oxidative stress. | Duan, Q., et al. 2020. Bioengineered. 11: 801-810. PMID: 32693689
- Narciclasine attenuates sepsis-induced myocardial injury by modulating autophagy. | Tang, R., et al. 2021. Aging (Albany NY). 13: 15151-15163. PMID: 34035183
- Narciclasine induces autophagy-mediated apoptosis in gastric cancer cells through the Akt/mTOR signaling pathway. | Yuan, Y., et al. 2021. BMC Pharmacol Toxicol. 22: 70. PMID: 34753517
- Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells. | Lv, C., et al. 2022. Mol Ther Oncolytics. 24: 340-354. PMID: 35118192
- Narciclasine suppresses esophageal cancer cell proliferation and migration by inhibiting the FAK signaling pathway. | Qiu, Y., et al. 2022. Eur J Pharmacol. 921: 174669. PMID: 35248554
- Narciclasine ameliorated T cell mediated acute liver injury through activating AMPK pathway. | Tian, Y., et al. 2022. Cell Immunol. 382: 104631. PMID: 36272268
- Narciclasine suppresses oral cancer metastasis by modulating cathepsin B and extracellular signal-related kinase pathways. | Shieu, MK., et al. 2023. Biomed Pharmacother. 158: 114159. PMID: 36577331
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Narciclasine, 1 mg | sc-361271 | 1 mg | $169.00 | |||
Narciclasine, 10 mg | sc-361271A | 10 mg | $1100.00 | |||
Narciclasine, 30 mg | sc-361271B | 30 mg | $4000.00 |